Katherine E. Watkins
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katherine E. Watkins has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Harold Alan Pincus
2 shared publicationsM. Audrey Burnam
RAND Corporation, Santa Monica, CA, USA
2 shared publicationsSarah B. Hunter
2 shared publicationsAnne Griffin
RAND, 1700 Main St., Santa Monica, California, 90407‐2138, USA
1 shared publicationGina Nicholson
1 shared publicationHaiden A. Huskamp
Harvard Medical School, Boston, MA, USA
1 shared publication
Latest Publications
- 1 January 2009
- Published by Elsevier in Value in Health
- Vol. 12 (1) , 65-72
The Health Value and Cost of Care for Major Depression
- 1 January 2009
- Published by Elsevier in Value in Health
- Vol. 12 (1) , 65-72
The Health Value and Cost of Care for Major Depression
- 1 December 2006
- Published by SAGE Publications in Professional School Counseling
- Vol. 10 (2)
An Update on Adolescent Drug Use: What School Counselors Need to Know
School counselors need to have accurate and age-appropriate prevention education information in order to counsel teens on drug use. This article presents developmentally specific prevention materials for the most important emerging substances of abuse: Ecstasy, methamphetamine, cough and cold medication, prescription opiates and stimulants, and the “date rape” drugs. Because developing appropriate materials requires understanding how adolescents develop, an expert panel approach was used, supplemented with a literature review and teen focus groups.
- 1 December 2006
- Published by SAGE Publications in Professional School Counseling
- Vol. 10 (2)
An Update on Adolescent Drug Use: What School Counselors Need to Know
School counselors need to have accurate and age-appropriate prevention education information in order to counsel teens on drug use. This article presents developmentally specific prevention materials for the most important emerging substances of abuse: Ecstasy, methamphetamine, cough and cold medication, prescription opiates and stimulants, and the “date rape” drugs. Because developing appropriate materials requires understanding how adolescents develop, an expert panel approach was used, supplemented with a literature review and teen focus groups.
- 1 August 2005
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 56 (8) , 913-926
Review of Treatment Recommendations for Persons With a Co-occurring Affective or Anxiety and Substance Use Disorder
The authors review and evaluate the literature and guidelines on care for individuals with a co-occurring affective or anxiety disorder and substance use disorder. MEDLINE and PsycINFO computerized searches of the English language literature were conducted for the period 1990-2002. These articles were supplemented with searches of the Cochrane Database of Systematic Reviews (1990 to 2002) and with articles that were sent to the authors by experts in the field to review. Bibliographies of selected papers were hand searched for additional articles. From these searches a total of 219 articles were found, of which 127 were selected for review. The literature shows that, over the past several decades, treatment for co-occurring disorders has undergone a broad shift in approach, from treating substance abuse before providing mental health care to providing simultaneous treatment for each disorder, regardless of the status of the comorbid condition. Many treatment recommendations are supported by a broad consensus. However, despite this broad agreement, recommendations are often not specific enough to guide clinical care. Most recommendations with specificity are for acute pharmacotherapy, but even specific recommendations lag behind current clinical practice. Although the use of psychotropic medication for mental illness is encouraged, experts disagree as to whether it is necessary to wait for abstinence before beginning pharmacotherapy. In addition, most diagnosis-specific guidelines are silent as to whether the specific treatment recommendation applies to co-occurring disorders. Finally, empirical evidence is lacking for most recommendations. The authors conclude that the mental health and substance abuse treatment fields need to consider its research priorities and how to address the multitude of potential combinations of disorders.
- 1 August 2005
- Published by American Psychiatric Association Publishing in Psychiatric Services
- Vol. 56 (8) , 913-926
Review of Treatment Recommendations for Persons With a Co-occurring Affective or Anxiety and Substance Use Disorder
The authors review and evaluate the literature and guidelines on care for individuals with a co-occurring affective or anxiety disorder and substance use disorder. MEDLINE and PsycINFO computerized searches of the English language literature were conducted for the period 1990-2002. These articles were supplemented with searches of the Cochrane Database of Systematic Reviews (1990 to 2002) and with articles that were sent to the authors by experts in the field to review. Bibliographies of selected papers were hand searched for additional articles. From these searches a total of 219 articles were found, of which 127 were selected for review. The literature shows that, over the past several decades, treatment for co-occurring disorders has undergone a broad shift in approach, from treating substance abuse before providing mental health care to providing simultaneous treatment for each disorder, regardless of the status of the comorbid condition. Many treatment recommendations are supported by a broad consensus. However, despite this broad agreement, recommendations are often not specific enough to guide clinical care. Most recommendations with specificity are for acute pharmacotherapy, but even specific recommendations lag behind current clinical practice. Although the use of psychotropic medication for mental illness is encouraged, experts disagree as to whether it is necessary to wait for abstinence before beginning pharmacotherapy. In addition, most diagnosis-specific guidelines are silent as to whether the specific treatment recommendation applies to co-occurring disorders. Finally, empirical evidence is lacking for most recommendations. The authors conclude that the mental health and substance abuse treatment fields need to consider its research priorities and how to address the multitude of potential combinations of disorders.
- 1 January 2004
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 30 (4) , 749-764
Prevalence and Characteristics of Clients with Co‐Occurring Disorders in Outpatient Substance Abuse Treatment
This article reports on the prevalence of probable mental health disorders among clients entering outpatient substance abuse treatment, their clinical characteristics, and past access to substance ...
- 1 January 2004
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 30 (4) , 749-764
Prevalence and Characteristics of Clients with Co‐Occurring Disorders in Outpatient Substance Abuse Treatment
This article reports on the prevalence of probable mental health disorders among clients entering outpatient substance abuse treatment, their clinical characteristics, and past access to substance ...
- 1 March 2003
- Published by Alcohol Research Documentation, Inc. in Journal of Studies on Alcohol
- Vol. 64 (2) , 209-218
Using the chronic care model to improve treatment of alcohol use disorders in primary care settings.
Alcohol use disorders (AUDs) are serious and often chronic medical conditions that present a significant public health concern. The Chronic Care Model (CCM), originally designed to improve care for patients with chronic conditions, is also applicable to a broad range of individuals with AUDs. In this article, we describe the CCM and discuss ways it can be adapted in primary care settings to improve care for AUDs. We review the evidence for considering the spectrum of AUDs as a chronic disease and discuss how the CCM might guide the reorganization of care to improve the delivery of effective interventions in primary care settings. We also solicited specific advice and feedback from an expert panel by means of a listserv. The CCM is a heuristic model that offers an approach to increase the ability of PCPs to identify, treat and effectively manage AUDs. Research suggests the model works well for a variety of chronic illnesses and across a number of different organizational settings. Implementation of the model in the case of AUDs has the potential to improve their care. Given the potentially chronic and relapsing nature of AUDs, it is important for the alcohol treatment community to be aware of the current research on improving care for chronic illnesses and to consider how the CCM might be adapted to improve care for AUDs. Further work is needed on developing tools, self-management support resources and training strategies before the CCM can be evaluated in real world settings.
- 1 March 2003
- Published by Alcohol Research Documentation, Inc. in Journal of Studies on Alcohol
- Vol. 64 (2) , 209-218
Using the chronic care model to improve treatment of alcohol use disorders in primary care settings.
Alcohol use disorders (AUDs) are serious and often chronic medical conditions that present a significant public health concern. The Chronic Care Model (CCM), originally designed to improve care for patients with chronic conditions, is also applicable to a broad range of individuals with AUDs. In this article, we describe the CCM and discuss ways it can be adapted in primary care settings to improve care for AUDs. We review the evidence for considering the spectrum of AUDs as a chronic disease and discuss how the CCM might guide the reorganization of care to improve the delivery of effective interventions in primary care settings. We also solicited specific advice and feedback from an expert panel by means of a listserv. The CCM is a heuristic model that offers an approach to increase the ability of PCPs to identify, treat and effectively manage AUDs. Research suggests the model works well for a variety of chronic illnesses and across a number of different organizational settings. Implementation of the model in the case of AUDs has the potential to improve their care. Given the potentially chronic and relapsing nature of AUDs, it is important for the alcohol treatment community to be aware of the current research on improving care for chronic illnesses and to consider how the CCM might be adapted to improve care for AUDs. Further work is needed on developing tools, self-management support resources and training strategies before the CCM can be evaluated in real world settings.